However, the preventive and treatment effects of available COX-2 inhibitors (aspirin and celecoxib) on CRC are not ideal, and most CRC patients failed to respond to the available COX-2 inhibitors. This evidence concerns the gene PTGS2 and colorectal carcinoma.